Novo Nordisk A/S
NVO
$122.75
-$1.78-1.43%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 34.69% | 26.70% | 19.38% | 13.52% | 11.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.69% | 26.70% | 19.38% | 13.52% | 11.87% |
| Cost of Revenue | 29.05% | 26.85% | 15.77% | 7.66% | 6.97% |
| Gross Profit | 35.77% | 26.67% | 20.08% | 14.68% | 12.86% |
| SG&A Expenses | 24.90% | 17.97% | 14.66% | 10.63% | 9.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 88.31% | 28.68% | 37.22% | 16.45% | -103.94% |
| Total Operating Expenses | 30.01% | 25.09% | 18.14% | 12.17% | 10.76% |
| Operating Income | 40.96% | 28.84% | 21.06% | 15.33% | 13.38% |
| Income Before Tax | 55.17% | 40.57% | 23.87% | 11.76% | 4.04% |
| Income Tax Expenses | 58.46% | 37.79% | 21.70% | 13.37% | 6.48% |
| Earnings from Continuing Operations | 54.37% | 41.26% | 24.39% | 11.37% | 3.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.37% | 41.26% | 24.39% | 11.37% | 3.46% |
| EBIT | 40.96% | 28.84% | 21.06% | 15.33% | 13.38% |
| EBITDA | 39.39% | 29.59% | 22.26% | 16.57% | 15.12% |
| EPS Basic | 56.07% | 42.95% | 25.97% | 12.87% | 4.90% |
| Normalized Basic EPS | 55.99% | 43.27% | 26.58% | 14.49% | 6.78% |
| EPS Diluted | 56.05% | 42.93% | 25.92% | 12.86% | 4.85% |
| Normalized Diluted EPS | 56.03% | 43.29% | 26.56% | 14.44% | 6.73% |
| Average Basic Shares Outstanding | -1.06% | -1.14% | -1.22% | -1.30% | -1.36% |
| Average Diluted Shares Outstanding | -1.08% | -1.15% | -1.20% | -1.25% | -1.31% |
| Dividend Per Share | 57.68% | 19.58% | 19.58% | 6.14% | 6.14% |
| Payout Ratio | -0.19% | -0.11% | -0.13% | -0.03% | 0.03% |
